SIG
NKTR icon

Stanford Investment Group’s Nektar Therapeutics NKTR Stock Holding History

Stanford Investment Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-18
Closed -$3K – 185
2016
Q4 		$3K Sell
18
-47
-72% -$9.56K ﹤0.01% 351
2016
Q3 		$17K Buy
+65
New +$16.7K 0.01% 269

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stanford Investment Group's NKTR Position: Q1 2017 in Review

Stanford Investment Group sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 18 shares — an estimated $3K sold.

Stanford Investment Group first reported a position in NKTR in Q3 2016 and held it in 2 quarters. The position peaked at $17K in Q3 2016. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

  • Stanford Investment Group reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 18 Nektar Therapeutics shares in Q1 2017, an estimated $3K.
  • Stanford Investment Group first reported a position in Nektar Therapeutics in Q3 2016 and held it in 2 quarters.
  • Stanford Investment Group's Nektar Therapeutics position peaked at $17K in Q3 2016.
  • 201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.